FNY Partners Fund’s Pacira BioSciences PCRX Stock Holding History

FNY Partners Fund’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,000	Closed	-$136K	–	989
2017 Q1	$136K	Buy	+3,000	New	+$130K	0.02%	422

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

DCM

Daruma Capital Management New York $879M AUM 2.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FNY Partners Fund's PCRX Position: Q2 2017 in Review

FNY Partners Fund sold out of Pacira BioSciences (PCRX) in Q2 2017, closing a stake of 3,000 shares — an estimated $136K sold.

FNY Partners Fund first reported a position in PCRX in Q1 2017 and held it in 1 quarter. The position peaked at $136K in Q1 2017. 196 funds tracked by Wall St. Rank hold PCRX as of Q2 2017.

FNY Partners Fund reported no remaining Pacira BioSciences position as of Q2 2017 after selling out during the quarter.
FNY Partners Fund sold 3,000 Pacira BioSciences shares in Q2 2017, an estimated $136K.
FNY Partners Fund first reported a position in Pacira BioSciences in Q1 2017 and held it in 1 quarter.
FNY Partners Fund's Pacira BioSciences position peaked at $136K in Q1 2017.
196 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2017.

Based on FNY Partners Fund's 13F filing for Q2 2017, filed 10 Aug 2017.